Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Impact · against what's priced in

Valneva's positive Phase 2 results for its Shigella vaccine candidate provide a catalyst for forward growth expectations. The success of the immunogenicity and CHIM trials clears the path for Phase 3 development, introducing new potential value to the pipeline.

Scored by the NIS engine · methodology.

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

healthcare▲2%
biotech
pharmaceuticals
clinical trials
immunogenicity
vaccine

Top 1 mover · tap to explore

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

What matters in this story

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

What matters in this story

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Track these names every morning.

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

What matters in this story

Next reads from the same story arc

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

What matters in this story

Next reads from the same story arc

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Track these names every morning.

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law